The Future of Medicine Will Be Built With Cells.
IXI science develops next-generation mesenchymal stem cell and extracellular vesicle platforms designed for scalable regenerative applications.
From translational research to clinical innovation — we create the biological systems that enable real therapeutic progress.
Products & Services
Our products
HACI
Hydrogel-based Allogenic chondrocyte implantation
Studies suggest that HACI provides similar efficacy as the scaffold variant without requiring invasive surgery for implanting the scaffold.
Benefits
- HACI combines hydrogel scaffolds with allogenic chondrocytes to promote tissue regeneration and restore cartilage function. The hydrogel offers a supportive environment for chondrocytes, enhancing their survival, proliferation, and integration with the host tissue. This method provides several benefits, including reduced immunogenicity, faster recovery, and improved clinical outcomes in joint repair, without the need for autologous tissue harvesting.
Applications
- Osteoarthritis Treatment
- Sports Injuries
- Joint Reconstruction
Components
Our materials
hMSCs
Mesenchymal Stem Cells from Wharton’s Jelly
These cells are ideal for regenerative medicine research, tissue engineering, inflammation modulation, and more.
Benefits
- High viability and purity
- Proven regenerative properties
- Versatility in research applications
Applications
- Tissue engineering
- Inflammation modulation
- Cellular therapies
Specifications
General
| Vial volume | 2ml |
| Vial temp | -196°C to -80°C |
| Cell count | 10M cells/vial |
| Cell viability | >80% |
Identification
| CD90+ | 99.5% |
| CD73+ | 99.2% |
| CD133- | 0.077% |
| CD(34+/45-) | 0.115% |
hHSCs
Hematopoietic Stem Cells from Umbilical Cord Blood
These cells are essential for studies in hematopoiesis, immune system research, and gene therapy.
Benefits
- High cell count and purity
- Essential for hematopoiesis research
- Reliable source for immune system studies
Applications
- Hematopoiesis research
- Immune system studies
- Gene therapy
Specifications
General
| Vial volume | 2ml |
| Vial temp | -196°C to -80°C |
| Cell count | 10M cells/vial |
| Cell viability | >80% |
Identification
| CD90+ | 70% |
| CD73+ | 6.5% |
| CD105+ | 0.8% |
| CD(45-/90+) | 4.55% |
| CD(45-/90+/73+/105+) | 0.2% |
| CD(34+/45+) | 0.3% |
ExoCell
Exosomes from Wharton’s Jelly derived hMSC
ExoCell contains a multitude of growth factors that enhance cellular and biochemical events, making it an invaluable tool for regenerative and therapeutic research.
Benefits
- Rich in growth factors
- Enhances cellular and biochemical events
- Ideal for regenerative and therapeutic research
Applications
- Regenerative medicine
- Therapeutic research
- Cellular communication studies
Specifications
TBD
Team
Lelle Hagström
Chief executive officer (CEO)
Lorena Moreno
Chief reputation officer (CRO)
Sonny Berg
Regional Director of Sales
Expert Group
Placeholder Name
Placeholder Title & Position
Placeholder Name
Placeholder Title & Position
Placeholder Name
Placeholder Title & Position
Our Vision
To become a global leader in regenerative medicine, delivering science-driven solutions that extend human healthspan, enhance wellness, and redefine preventive healthcare.
Our Values
Science First – We build on evidence, innovation, and rigorous research.
Integrity – Ethical, transparent, and responsible in everything we do.
Sustainability – Committed to environmental and social responsibility.
Human Impact – Improving lives is at the core of our mission.
Our Policies
We are committed to strict compliance with Good Manufacturing Practice (GMP) standards, ethical sourcing of biological materials, and alignment with international regulatory frameworks. As we grow, our Environmental, Social, and Governance (ESG) principles will guide long-term strategy and decision-making.